Following further reports from our supporters of concerns about the availability of EpiPen® in the UK, the Anaphylaxis Campaign have contacted Mylan who distribute EpiPen® in the UK for further updates regarding a supply issue.
Mylan have confirmed with us that Junior EpiPens® are unaffected.
However, there are supply constraints of Senior EpiPen® due to manufacturing delays from their contract manufacturer, Meridian Medical Technologies, a Pfizer company. As a result, some steps are being put in place to assist in the stock management. Mylan have provided us with a statement to explain this, which is detailed below.
EpiPen® is an adrenaline auto-injector used for the emergency treatment of severe allergic reactions known as anaphylaxis and is a prescription only medicine.
If you have been prescribed an EpiPen® (Senior) Adrenaline Auto-Injector, to be well equipped during this time, we advise you to
- Check the expiry date on your medication
- If needed, get a repeat prescription from your GP well in advance
- Print out a copy of this statement to bring with you to your pharmacy
- Ask your pharmacist to contact Mylan via Alliance Healthcare for an update if they are experiencing any supply issues
The pharmaceutical companies who distribute Adrenaline Auto-Injectors have their own customer care departments and formal complaints procedures. If you have any concerns we encourage feedback to be given directly to the organisations responsible. Please speak to Mylan customer services in the first instance on +44 (0)1707 853 100.
You can also contact our helpline and information team at email@example.com or call 01252 542 029 for support.
UPDATE: Availability of EpiPen® (Senior) 0.3mg Adrenaline Auto-Injector
Dear Anaphylaxis Campaign,
Due to manufacturing delays from our contract manufacturer, Meridian Medical Technologies, a Pfizer company, there are intermittent supply constraints of EpiPen® 0.3mg (Senior) Adrenaline Auto-Injector in the UK. At this time, there are no supply constraints of EpiPenJr® 0.15mg Adrenaline Auto-Injectors.
Our first priority is to ensure patients at risk for a potentially life-threatening allergic reaction (anaphylaxis) have access to adrenaline auto-injector products. Mylan is working closely with Pfizer to manage supply carefully to avoid long-term supply shortages. Pfizer anticipates that production rates will increase over the coming months; however, at this time, cannot commit to a specific time for when the supply constraint will be fully resolved.
To further assist in the stock management of EpiPen® 0.3mg (Senior), pharmacies are allocating stock on a prescription-only basis and are placing orders for up to a maximum of two EpiPen® 0.3mg (Senior) Auto-Injectors per prescription.
Mylan is unable to make any specific treatment recommendation to individual patients. Patients should speak to their healthcare provider for appropriate actions to be taken. Please note, when validating the expiry date of an adrenaline auto-injector, the product expires on the last day of the month indicated. For example, if it expires in March, it remains valid (not expired) until March 31.
We are confident in the safety and efficacy of the EpiPen® products being produced at the site and are working closely with Pfizer to alleviate the situation and achieve a steady state of supply as expeditiously as possible.
If you require additional information or have any questions, please contact +44(0) 1707 853 100.